Steven Pavletic
Corey Cutler
Andrew HarrisWhat are the key barriers to patient participation in cGvHD clinical trials?
The GvHD Hub spoke with Steven Pavletic, Bethesda, US. We asked, What are the key barriers to patient participation in cGvHD clinical trials?
All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know GvHD.
TRANSLATE
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GVHD Hub is an independent medical education platform, sponsored by Medac and supported through independent educational grants from Incyte, Sanofi and Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View GvHD content recommended for you
Masterclass | Addressing barriers to patient participation in cGvHD clinical trials
Clinical trials provide an important opportunity to improve understanding of chronic-graft-versus host disease (cGvHD) and evaluate new prevention and treatment approaches. However, patient participation in clinical trials can be influenced by a range of factors, including practical, emotional, and clinical considerations.1–3 Understanding these factors may help inform approaches to better support patients throughout the clinical trial process.
The GvHD Hub spoke with Steven Pavletic, Andrew Harris, and Corey Cutler to gain their expert insights regarding key barriers to patient participation in cGvHD clinical trials, as well as possible approaches to address these challenges.
What are the challenges involved in enrolling pediatric patients in cGvHD clinical trials?
The GvHD Hub spoke with Andrew Harris, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are the challenges involved in enrolling pediatric patients in cGvHD clinical trials?
What approaches could improve recruitment and retention in cGvHD clinical trials?
The GvHD Hub spoke with Corey Cutler, Dana-Farber Cancer Institute, Boston, US. We asked, What approaches could improve recruitment and retention in cGvHD clinical trials?
This educational resource is independently supported by Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
.webp)
